Reoxygenation After Cardiac Arrest II (REOX II Study)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Cardiac Arrest
Interventions
OTHER

Protocol for rapid FiO2 optimization

"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."

Trial Locations (5)

19104

Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center, Philadelphia

39216

University of Mississippi Medical Center, Jackson

46202

Indiana University/ Methodist Hospital, Indianapolis

02215

Beth Israel Deaconess Medical Center, Boston

08103

Cooper University Hospital, Camden

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The Cooper Health System

OTHER

NCT02698826 - Reoxygenation After Cardiac Arrest II (REOX II Study) | Biotech Hunter | Biotech Hunter